Takahito Moriyama

Takahito Moriyama

Auto-generated profile, based on publicly available information

Takahito Moriyama

Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTakahito Moriyama
Takahito Moriyama
KTKayu Tanaka
Kayu Tanaka
CIChihiro Iwasaki
Chihiro Iwasaki
YOYasuko Oshima
Yasuko Oshima
AOAyami Ochi
Ayami Ochi
KNKosaku Nitta
Kosaku Nitta
Little is known about the long-term prognosis of patients with IgA nephropathy (IgAN). This retrospective cohort analysis evaluated clinical and histological findings at the time of renal biopsy, initial treatment, patient outcomes over 30 years, and risk factors associated with progression in 1,012 patients diagnosed with IgAN at our center since 1974. Of the 1,012 patients, 40.5% were male. Mean patient age was 33±12 years and mean blood pressure was 122±17/75±13 mmHg. Mean serum creatinine concentration was 0.89±0.42 mg/dL, and mean estimated glomerular filtration rate (eGFR) was 78.5±26.2 ml/min/1.73 m2. Mean proteinuria was 1.19±1.61 g/day, and mean urinary red blood cells were 36.6±35.3/high-powered field. Histologically, mesangial hypercellularity was present in 47.6% of patients, endothelial hypercellularity in 44.3%, segmental sclerosis in 74.6%, and tubular atrophy/interstitial fibrosis in 28.8% by Oxford classification. Initial treatment consisted of corticosteroids in 26.9% of patients, renin-angiotensin-aldosterone system inhibitor in 28.9%, and tonsillectomy plus steroids in 11.7%. The 10-, 20-, and 30-year renal survival rates were 84.3, 66.6, and 50.3%, respectively. Tonsillectomy plus steroids dramatically improved renal outcome. Cox multivariate regression analysis showed that higher proteinuria, lower eGFR, and higher uric acid at the time of renal biopsy were independent risk factors for the development of end stage renal disease (ESRD). IgAN is not a benign disease, with about 50% of patients progressing to ESRD within 30 years despite treatment.

9 April 2019 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
TMTakahito Moriyama
Takahito Moriyama

30 October 2014 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
TMTakahito Moriyama
Takahito Moriyama
MIMitsuyo Itabashi
Mitsuyo Itabashi
TTTakashi Takei
Takashi Takei
HKHiroshi Kataoka
Hiroshi Kataoka
MSMasayo Sato
Masayo Sato
KNKosaku Nitta
Kosaku Nitta
High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear. Adult IgAN patients (n = 611) were classified according to CKD stage. Renal survival rates and clinical and histological findings were compared between patients with high (H-UA) and normal (N-UA) uric acid levels in different CKD stages. The proportion of patients with H-UA increased significantly with increasing CKD stage (stage G1, 12.3 %; stage G2, 19.0 %; stage G3a, 43.7 %; stage G3b–4, 69.0 %; P < 0.001). The 30-year renal survival rate was similar in patients with H-UA and N-UA in CKD stages G1, G2, and G3b–4, but was significantly lower in patients with H-UA than with N-UA in CKD stage G3a (24.7 vs. 51.9 %; P = 0.0205). The clinical findings were similar in patients with H-UA and N-UA, but the interval from onset to biopsy differed between groups. The proportion of patients with global sclerosis was significantly higher in patients with H-UA than with N-UA in CKD stage G3a (33.3 vs. 11.4 %; P = 0.0005), but the Oxford classifications were similar between groups. Multivariate Cox regression analysis identified H-UA (HR 1.36, 95 % CI 1.07–1.72, P = 0.011) and a large amount of proteinuria (HR 1.38, 95 % CI 1.09–1.74, P = 0.0084) as independent predictors of end-stage renal disease. H-UA induced global glomerular sclerosis and accelerated the progression of IgAN in CKD stage G3a.

14 October 2021 in Kidney International Reports
Verified
Journal Article
Open access
SIShusaku Itami
Shusaku Itami
TMTakahito Moriyama
Takahito Moriyama
YMYoei Miyabe
Yoei Miyabe
KKKazunori Karasawa
Kazunori Karasawa
KNKosaku Nitta
Kosaku Nitta
The usefulness of the Oxford classification (MEST-C score) for deciding the management approach for IgA nephropathy (IgAN) remains unclear. Effects of steroid therapy on the long-term prognosis for all 858 patients with IgAN and patients classified according to each MEST-C score were evaluated using Kaplan-Meier and Cox regression analyses. Steroid responder score (SRS) and steroid nonresponder score (SNRS) were determined using individual pathology scores when steroids were found to be independently associated, or not, with clinical benefits. In addition, the effects of steroid therapy according to the total SRS/SNRS were analyzed. Steroid therapy improved the 20-year renal survival rates of patients with IgAN after matching (steroids[+] vs. steroids[−]; estimated glomerular filtration rate [eGFR] [ml/min per 1.73 m2]: 79.4 vs. 77.0, not significant; proteinuria [g/d]: 0.80 vs. 0.62, not significant; renal survival rate: 75.5% vs. 61.7%; P = 0.025) and of patients with M1, E1, S1, C1+2, and T0 scores. Therefore, we considered the total of the M1, E1, S1, and C1+2 scores (point 0: low, 1–2: medium, and 3–4: high) as the SRS and the total of the T1+2 scores (0: low and 1: high) as the SNRS. Multivariate Cox regression analyses revealed that steroid therapy improved the renal prognosis of patients with IgAN with high SRS and any SNRS, unlike patients with IgAN with medium SRS and any SNRS. Patients with M1, E1, S1, and C1+2 scores responded to steroid therapy; however, those with T1+2 scores did not. Although a high SRS was a useful indicator for steroid therapy, SNRS indicated resistance to steroid therapy.

7 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TMTakahito Moriyama
Takahito Moriyama
KKKazunori Karasawa
Kazunori Karasawa
YMYoei Miyabe
Yoei Miyabe
KAKenichi Akiyama
Kenichi Akiyama
SOShota Ogura
Shota Ogura
KNKosaku Nitta
Kosaku Nitta
The Oxford classification for IgA nephropathy (IgAN) was updated in 2017. We have validated the revised Oxford classification considering treatment with corticosteroids/immunosuppressors. In this retrospective analysis, 871 IgAN patients were enrolled. Patients were divided into two groups, those treated with or without corticosteroids/immunosuppressors. The 20-year renal prognosis up to end-stage renal disease was assessed using the Oxford classification. In all patients, the renal survival rate was 87.5% at 10 years and 72.6% at 20 years. The T score alone was significantly related to renal prognosis in the Kaplan–Meier analysis and multivariate Cox regression analysis. In the non-treatment group (n = 445), E, S, T, and C scores were significantly related to renal survival rates, however, in the treatment group (n = 426), T score alone was significantly related to renal prognosis on Kaplan–Meier analysis, indicating that corticosteroids/immunosuppressors improved renal prognosis in E1, S1, and C1. In patients with E1, S1, or C1, the treatment group showed significantly better renal prognosis than the non-treatment group in univariate and multivariate analysis. The Oxford classification and T score were used to determine renal prognosis in IgAN patients. Corticosteroids/immunosuppressors improved renal prognosis, especially E1, S1, and C1 scores.

30 March 2011 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
TMTakahito Moriyama
Takahito Moriyama
YTYuki Tsuruta
Yuki Tsuruta
ASAri Shimizu
Ari Shimizu
MIMitsuyo Itabashi
Mitsuyo Itabashi
TTTakashi Takei
Takashi Takei
KNKosaku Nitta
Kosaku Nitta
Aims The aim of this study was to demonstrate expression of cell membrane invagination ‘caveolae’ in glomeruli and to correlate this with functional and structural characteristics of the human glomerular diseases. Methods The expression of caveolin-1 (Cav-1), which is the main component of caveolae, was examined in the glomeruli, and the relationship between Cav-1 expression and pathological and clinical findings was determined in 99 patients with glomerular disease and in 50 renal transplantation donors as controls. Results Cav-1 was expressed very weakly in the controls, and the area of Cav-1 expression relative to the total glomerular area was 0.57±0.65%. However, the area of Cav-1 expression was significantly larger in each glomerular disease (IgA nephropathy, 1.05±1.36%, p<0.05; crescent glomerulonephritis, 1.86±1.19%, p<0.001; minimal change disease, 2.38±1.24%, p<0.001; focal segmental glomerulosclerosis, 2.88±2.05%, p<0.01; membranous nephritis, 4.27±2.95%, p<0.001; membranoproliferative glomerulonephritis, 4.49±3.15%, p<0.001; and diabetic nephropathy, 2.45±1.52%, p<0.001; compared with the controls. Cav-1 expression was significantly decreased in glomerular disease treated with steroids. Co-localisation of Cav-1 and the endothelial marker ‘pathologische anatomie leiden-endothelium’ was prominent in an immunofluorescence study, and caveolae on the glomerular endothelial cells were observed in electron microscopy. Conclusions The expression of Cav-1 was significantly increased in the glomeruli of patients with glomerular disease, and it was related to urinary albumin excretion. Cav-1 expression and caveolae were observed in glomerular endothelial cells. It is hypothesised that they play a role in the recovery phase of capillary injury or endocytosis of albumin into endothelial cells. Basic research should be performed to elucidate the role played by Cav-1 and caveolae.